The effect of perospirone on auditory P300 in schizophrenia: A preliminary study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 6, 2006, Pages 1083-1090

  Araki, Tsuyoshi ^a,b   Kasai, Kiyoto ^a   Rogers, Mark A ^a   Kato, Nobumasa ^a   Iwanami, Akira ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Auditory P300; Event related potentials (ERPs); Perospirone; Schizophrenia; Second generation antipsychotics

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; LEVOMEPROMAZINE; PEROSPIRONE; RISPERIDONE; SULPIRIDE;

ADULT; ARTICLE; ATTENTION DISTURBANCE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DELUSION; DEPRESSION; DRUG EFFECT; DRUG SUBSTITUTION; ELECTROPHYSIOLOGY; EMOTIONAL DISORDER; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; FEMALE; HALLUCINATION; HUMAN; LATENT PERIOD; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DATA INTERPRETATION, STATISTICAL; ELECTROPHYSIOLOGY; EVENT-RELATED POTENTIALS, P300; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES;

EID: 33745237707     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.04.009     Document Type: Article

References (41)

1. Andreasen N.C., Nopoulos P., O'Leary D.S., Miller D.D., Wassink T., and Flaum M. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanism. Biol Psychiatry 46 (1999) 908-920
2. Araki T., Yamasue H., Sumiyoshi T., Kuwabara H., Suga M., Iwanami A., et al. Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog Neuro-Psychopharmacol Biol Psychiatry 30 (2006) 204-208
3. Casey D.E. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 35 Suppl. 1 (1999) S61-S66
4. Diaz-Mataix L., Scorza M.C., Bortolozzi A., Toth M., Celada P., and Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25 (2005) 10831-10843
5. Donchin E., and Coles M. Is the P300 component a manifestation of context updating?. Behav Brain Sci 11 (1988) 357-374
6. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I disorders. New York: Biometrics Research Department, New York State Psychiatric Institute (1997), Nihon Hyoron-sha publishers, Tokyo (Japanese translation: Kitamura T, Okano T (2003).)
7. Ford J.M. Schizophrenia: broken P300 and beyond. Psychophysiology 36 (1999) 667-682
8. Gallinat J., Riedel M., Juckel G., Sokullu S., Frodl T., Moukhtieva R., et al. P300 and symptom improvement in schizophrenia. Psychopharmacology 158 (2001) 55-65
9. Gonul A.S., Suer C., Coburn K., Ozesmi C., Oguz A., and Yilmaz A. Effects of olanzapine on auditory P300 in schizophrenia. Prog Neuro-psychopharmacol Biol Psychiatry 27 (2003) 173-177
10. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 153 (1996) 321-330
11. Harvey P.D., and Keefe R.S.E. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158 (2001) 176-184
12. Inagaki A., Inada T., Fujii Y., and Yagi G. Dose equivalence of neuroleptics. In: Inagaki A., Inada T., Fujii Y., Yagi G., Yoshio T., Nakamura H., et al. (Eds). Dose Equivalence of Psychotropic Drugs (1999), Seiwa Publishers, Tokyo 11-60
13. Inagaki A., Inada T., Fujii Y., and Yagi G. Dose equivalence of neuroleptics. In: Inagaki A., Inada T., Fujii Y., Yagi G., Yoshio T., Nakamura H., et al. (Eds). Dose Equivalence of Anti-Cholinergic Drugs (1999), Seiwa Publishers, Tokyo 61-76
14. Inagaki A., Inada T., Fujii Y., and Yagi G. Dose of equivalence of psychotropic drugs. Part XV-dose of novel neuroleptics. Perospirone. Jpn J Clin Psychopharmacol 4 (2001) 869-870
15. Iwakawa M., Terao T., Soya A., Kojima H., Inoue Y., Ueda N., et al. A novel antipsychotic, perospirone, has antiserotonergic and antidopaminergic effects in human brain: findings from neuroendocrine challenge tests. Psychopharmacology 176 (2004) 407-411
16. Iwanami A., Okajima Y., Isono H., Shinoda J., Kasai K., Hata A., et al. Effects of risperidone on event-related potentials in schizophrenic patients. Pharmacopsychiatry 34 (2001) 73-79
17. Kato T., Hirose A., Ohno Y., Shimizu H., Tanaka H., and Nakamura M. Binding profile of SM-9018, a novel antipsychotic candidate. Jpn J Pharmacol 54 (1990) 478-481
18. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
19. Korostenskaja M., Dapsys K., Siurkute A., Maciulis V., Rsuksenas O., and Kahkonen S. Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders. Prog Neuro-Psychopharmacol Biol Psychiatry 29 (2005) 543-548
20. Mathalon D.H., Ford J.M., and Pfefferbaum A. Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol Psychiatry 47 (2000) 434-449
21. Mauskopf J., Muroff M., Gibson P.J., and Grainger D.L. Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia. Schizophr Bull 28 (2002) 619-635
22. McCarley R.W., Faux S.F., Shenton M.E., Nestor P.G., and Adams J. Event-related potentials in schizophrenia - their biological and clinical correlates and a new model of schizophrenic pathophysiology. Schizophr Res 4 (1991) 209-231
23. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25 (1999) 233-255
24. Molina V., Munoz F., Martin-Loeches M., Casado P., Hinojosa J.A., and Iglesias A. Long-term olanzapine treatment and p300 parameters in schizophrenia. Neuropsychobiology 50 (2004) 182-188
25. Moller H.J. Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci 249 Suppl. 4 (1999) S99-S107
26. Mori K., Nagao M., Yamashita H., Morinobu S., and Yamazaki S. Effect on switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 28 (2004) 659-665
27. Murasaki M., Yamashita I., Machiyama Y., Yagi G., Kamijima K., Kudo Y., et al. Early phase II study of a new antipsychotic, perospirone HCl (SM-9018), on schizophrenia. Kiso to Rinsho (Clinical Report) 31 (1997) 2159-2179
28. Niznikiewicz M.A., Patal J.K., McCarley R., Sutton J., Chau D.T., Wojcik J., et al. Clozapine action on auditory P3 response in schizophrenia. Schizophr Res 76 (2005) 119-121
29. Onrust S.V., and McClellan K. Perospirone. CNS Drugs 15 (2001) 329-337 discussion 338
30. Pallanti S., Quercioli L., and Pazzagli A. Effects of clozapine on awareness of illness and cognition in schizophrenia. Psychiatry Res 86 (1999) 239-249
31. Polich J., and Kok A. Cognitive and biological determinants of P300: an integrated review. Biol Psychology 41 (1995) 103-146
32. Roth B.L., Hanizavareh S.M., and Blum A.E. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 174 (2004) 17-24
33. Schotte A., Bonaventure P., Janssen P.F., and Leysen J.E. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 69 (1995) 399-412
34. Sumiyoshi T., and Meltzer H.Y. Serotonin 1A receptors in memory function. Am J Psychiatry 161 (2004) 1505
35. Sumiyoshi T., Matsui M., Yamashita I., Nohara S., Uehara T., Kurachi M., et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory function in schizophrenia. J Clin Psychopharmacol 20 (2000) 386-388
36. Sumiyoshi T., Matsui M., Nohara S., Yamashita I., Kurachi M., Sumiyoshi C., et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158 (2001) 1722-1725
37. Sumiyoshi T., Matsui M., Yamashita I., Nohara S., Kurachi M., Uehara T., et al. The effect of tandospirone, a serotonin (1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49 (2001) 861-868
38. Tandon R., and Jibson M.D. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 14 (2002) 123-129
39. Umbricht D., Javitt D., Novak G., Bates J., Pollack S., Lieberman J., et al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 44 (1998) 716-725
40. Umbricht D., Javitt D., Novak G., Bates J., Pollack S., Lieberman J., et al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol 2 (1999) 299-304
41. Voruganti L., Cortese L., Owyeumi L., Kotteda V., Cernovsky Z., Zirul S., et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 57 (2002) 201-208